12 terminated. 12 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 12 | Terminated 12 |
| Phase 1 | 1 | Terminated 1 |
Follow Refractory Chronic Lymphocytic Leukemia: new trials by email Literature Review of Refractory Chronic Lymphocytic Leukemia trials Research Report on Refractory Chronic Lymphocytic Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study Daratumumab, Ibrutinib - Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2020-11-11 | 2025-12-30 |
| Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas DTRM-555 - Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Terminated | Zhejiang DTRM Biopharma | 55 | 2020-04-24 | 2025-01-08 |
| Lenalidomide and Obinutuzumab in Treating Patients With Recurrent or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Lenalidomide, Obinutuzumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2016-03-31 | 2022-09-28 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload deferasirox - Iron Overload, Accelerated Phase Chronic Myelogenous Leukemia | Phase 2 | Terminated | City of Hope Medical Center | 1 | 2010-07-01 | 2019-06-18 |
| Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer rituximab, mycophenolate mofetil, tacrolimus - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Terminated | University of Nebraska | 20 | 2009-12-10 | 2023-09-06 |
| Sunitinib in Treating Patients With Idiopathic Myelofibrosis sunitinib malate - Accelerated Phase Chronic Myelogenous Leukemia, Acute Undifferentiated Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 14 | 2006-09-01 | 2014-05-28 |
| Sorafenib in Treating Patients With Relapsed Chronic Lymphocytic Leukemia sorafenib tosylate - Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 5 | 2005-11-01 | 2014-05-07 |
| Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma fenretinide, rituximab - Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 32 | 2005-10-01 | 2014-10-06 |
| Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia alvocidib - B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 64 | 2005-04-01 | 2016-10-24 |
| CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia temsirolimus, laboratory biomarker analysis - Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 60 | 2004-05-01 | 2013-01-24 |
| Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer fludarabine phosphate, thalidomide - Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | Phase 2 | Terminated | National Cancer Institute (NCI) | 70 | 2002-03-01 | 2013-06-06 |
Leukemia, Lymphocytic, Chronic, B-Cell (12) · Lymphoma, Large B-Cell, Diffuse (6) · Lymphoma, Follicular (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Burkitt Lymphoma (4) · Lymphoma, B-Cell, Marginal Zone (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, Non-Hodgkin (4) · Blast Crisis (3) · Hodgkin Disease (3) · Leukemia, Hairy Cell (3) · Leukemia, Myeloid, Accelerated Phase (3) · Leukemia, Myeloid, Acute (3) · Leukemia, Prolymphocytic (3) · Lymphoma, Large-Cell, Immunoblastic (3)
Chronic Disease (12) · Disease Attributes (12) · Hematologic Diseases (12) · Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Leukemia, Lymphoid (12) · Neoplasms by Histologic Type (12) · Pathologic Processes (12) · Pathological Conditions, Signs and Symptoms (12) · Leukemia (11) · Leukemia, B-Cell (11) · Lymphatic Diseases (11) · Lymphoproliferative Disorders (11) · Neoplasms (11)
Rituximab (3) · Lenalidomide (2) · fludarabine phosphate (2) · Antilymphocyte Serum (1) · Busulfan (1) · Cyclophosphamide (1) · DTRMWXHS-12 (1) · Deferasirox (1) · Everolimus (1) · Fenretinide (1) · Immunosuppression Therapy (1) · Mycophenolic Acid (1) · Sirolimus (1) · Sorafenib (1) · Sunitinib (1)
National Cancer Institute (NCI) (6) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · University of Nebraska (1) · Zhejiang DTRM Biopharma (1)
United States (12)
Ajay Gopal (1) · Alessandra Ferrajoli (1) · Francis Giles (1) · John Byrd (1) · Mohamed Sorror (1) · Richard Furman (1) · Robert Bociek, MD (1) · Sikander Ailawadhi, M.D. (1) · Srdan Verstovsek (1) · Vinod Pullarkat, MD (1) · Wendy Stock (1)
PMID 19826119, PMID 22289993, PMID 24990615, PMID 25596730
N01CM17003 (1), N01CM62201 (1), N01CM62202 (1), N01CM62204 (1), N01CM62207 (1), P30CA015704 (1), P30CA036727 (1), R21CA119519 (1)